Get started
Sight Sciences, Inc.Sight Sciences, Inc.Sight Sciences, Inc.

Sight Sciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SGHT chart


Full chart

SGHT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪203.53 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.01 USD
Net income (FY)
‪−55.55 M‬ USD
Revenue (FY)
‪81.06 M‬ USD
Shares float
‪29.22 M‬
Beta (1Y)
1.07

Employees


Employees (FY)
214
Change (1Y)
−36 −14.40%
Revenue / Employee (1Y)
‪378.77 K‬ USD
Net income / Employee (1Y)
‪−259.57 K‬ USD

About Sight Sciences, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Paul Badawi
Website
sightsciences.com
Headquarters
Menlo Park
FIGI
BBG006BZHZC7
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

SGHT news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SGHT is 4.01 USD — it has increased by 6.65% in the past 24 hours. Watch Sight Sciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sight Sciences, Inc. stocks are traded under the ticker SGHT.
SGHT stock has risen by 3.08% compared to the previous week, the month change is a −28.01% fall, over the last year Sight Sciences, Inc. has showed a 56.03% increase.
We've gathered analysts' opinions on Sight Sciences, Inc. future price: according to them, SGHT price has a max estimate of 6.00 USD and a min estimate of 5.00 USD. Watch SGHT chart and read a more detailed Sight Sciences, Inc. stock forecast: see what analysts think of Sight Sciences, Inc. and suggest that you do with its stocks.
SGHT reached its all-time high on Aug 2, 2021 with the price of 42.57 USD, and its all-time low was 1.04 USD and was reached on Oct 27, 2023. View more price dynamics on SGHT chart.
See other stocks reaching their highest and lowest prices.
SGHT stock is 9.90% volatile and has beta coefficient of 1.07. Track Sight Sciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sight Sciences, Inc. there?
Today Sight Sciences, Inc. has the market capitalization of ‪203.53 M‬, it has decreased by −1.05% over the last week.
Yes, you can track Sight Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
Sight Sciences, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
SGHT earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.21 USD resulting in a −6.00% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about Sight Sciences, Inc. earnings.
Sight Sciences, Inc. revenue for the last quarter amounts to ‪20.16 M‬ USD, despite the estimated figure of ‪20.40 M‬ USD. In the next quarter, revenue is expected to reach ‪20.47 M‬ USD.
SGHT net income for the last quarter is ‪−11.07 M‬ USD, while the quarter before that showed ‪−12.33 M‬ USD of net income which accounts for 10.24% change. Track more Sight Sciences, Inc. financial stats to get the full picture.
No, SGHT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 214.00 employees. See our rating of the largest employees — is Sight Sciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sight Sciences, Inc. EBITDA is ‪−49.13 M‬ USD, and current EBITDA margin is −69.90%. See more stats in Sight Sciences, Inc. financial statements.
Like other stocks, SGHT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sight Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sight Sciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sight Sciences, Inc. stock shows the strong sell signal. See more of Sight Sciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.